TY - JOUR
T1 - Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone
AU - Bouman-Wammes, Esther W.
AU - de Klerk, John M.H.
AU - Bloemendal, Haiko J.
AU - Van Dodewaard-de Jong, Jocye M.
AU - Lange, Rogier
AU - ter Heine, Rob
AU - Verheul, Henk M.W.
AU - Van den Eertwegh, Alfons J.M.
N1 - Funding Information:
E.W. Bouman-Wammes and J.M. van Dodewaard-de Jong have received financial support for attending a congress from Sanofi Genzyme, H. Verheul has received research grants from Immunovo BV, Vitromics Healthcare, and Roche and has received honoraria as a member of an advisory board from Boehringer Ingelheim, Roche, and Merck. A.J.M. Van den Eertwegh has received research grants from Sanofi and a speaker honorarium from Astellas and is a member of the advisory board of Astellas. The remaining authors have stated that they have no conflicts of interest.
Funding Information:
E.W. Bouman-Wammes and J.M. van Dodewaard-de Jong have received financial support for attending a congress from Sanofi Genzyme , H. Verheul has received research grants from Immunovo BV , Vitromics Healthcare , and Roche and has received honoraria as a member of an advisory board from Boehringer Ingelheim, Roche, and Merck. A.J.M. Van den Eertwegh has received research grants from Sanofi and a speaker honorarium from Astellas and is a member of the advisory board of Astellas. The remaining authors have stated that they have no conflicts of interest.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/4
Y1 - 2019/4
N2 - For patients with castration-resistant prostate cancer metastatic to bone, treatment with radiopharmaceuticals is a promising but yet underutilized treatment option. In this review, we describe the effects on pain palliation and survival and the specific characteristics of the different radiopharmaceuticals as monotherapy or combined with chemotherapy.
AB - For patients with castration-resistant prostate cancer metastatic to bone, treatment with radiopharmaceuticals is a promising but yet underutilized treatment option. In this review, we describe the effects on pain palliation and survival and the specific characteristics of the different radiopharmaceuticals as monotherapy or combined with chemotherapy.
KW - Bone-metastases
KW - Combination therapy
KW - Metastatic disease
KW - Palliative treatment
KW - Radionuclide
UR - https://www.scopus.com/pages/publications/85058231885
U2 - 10.1016/j.clgc.2018.11.014
DO - 10.1016/j.clgc.2018.11.014
M3 - Review article
C2 - 30555024
SN - 1558-7673
VL - 17
SP - e281-e292
JO - Clinical genitourinary cancer
JF - Clinical genitourinary cancer
IS - 2
ER -
SDG 3 Good Health and Well-being